OPK logo

OPKO HEALTH INC

OPKNASDAQ
πŸ† #2249 by market capEarnings Nov 11US Equity
$1.66β–² $0.04 (+2.47%)
πŸŒ… Pre-market$1.64β–Ό 1.20%Regular close Β· extended-hours price shown
πŸ””
Track OPK
Get earnings, price moves & breaking news on Telegram
Track
24hβ–² 2.5%
7dβ–² 0.6%
14dβ–² 7.8%
30dβ–² 3.1%
ytdβ–² 32.8%
1yβ–² 13.3%
🏦Market Cap
$1.24B
Small Cap
πŸ“ˆRevenue Growth (YoY)
-14.9%
Declining
πŸ“ŠGross Margin
31.0%
Moderate
πŸ’΅FCF Margin
-22.8%
Thin
βš–οΈP/S Ratio
2.1x
Cheap
Otter Score
48
Weak

Trading Snapshot

Day Range
$1.61 – $1.67
52-Week Range
$0.98 – $1.77
Volume (shares)
1,976,509
Avg Volume (shares)
β€”
Shares Outstanding
746.3M
Next Earnings
2026-11-11

Fundamentals Snapshot

Annual Revenue
$607M
Last Q Revenue
$164M
P/E Ratio
-17.4
P/S Ratio
2.1x
EPS (TTM)
$-0.10
Dividend Yield
0.00%
Dilution (1yr)
+10.3%
OPK logo

OPKO HEALTH INC

OPK
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$607Mβ–Ό βˆ’14.9% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
21.1%β–Ό βˆ’51.6% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$219Mβ–² +44.0% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
βˆ’$191Mβ–Ό βˆ’8.5% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
765.5Mβ–² +10.3% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
βˆ’$65Mβ–² +$8M YoY
StockOtter Β· stockotter.space

About OPKO HEALTH INC

OPKO Health, Inc. operates as a healthcare enterprise with a dual focus on diagnostics and pharmaceuticals. Its operations span the United States, Ireland, Chile, Spain, Israel, Mexico, and other international markets. The company's Diagnostics division encompasses BioReference Laboratories, which delivers a comprehensive suite of laboratory testing services. These services are crucial for disease detection, diagnosis, evaluation, monitoring, and treatment, covering areas such as esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare. BioReference serves a diverse client base, including medical practices, clinics, hospitals, employers, and government entities. Additionally, this segment provides a cutting-edge diagnostic instrument system designed for immediate, point-of-care blood test results, alongside its specialized 4Kscore testing for prostate cancer. Within the Pharmaceutical segment, OPKO offers a range of therapeutic products and a robust development pipeline. Key offerings include Rayaldee, indicated for the management of secondary hyperparathyroidism in adults suffering from stage 3 or 4 chronic kidney disease and vitamin D insufficiency. The pipeline features OPK88004, an investigational orally administered selective androgen receptor modulator; OPK88003, a peptide administered once weekly currently in Phase IIb trials for the treatment of type 2 diabetes and obesity; and hGH-CTP, a once-weekly human growth hormone injection that has successfully completed Phase III clinical trials in collaboration with Pfizer, Inc. A core strategy for this segment involves the development and commercialization of proprietary, extended-release versions of existing therapeutic proteins. Furthermore, OPKO Health supplies specialty active pharmaceutical ingredients (APIs) and is involved in the development, manufacturing, marketing, and sale of pharmaceutical, nutraceutical, veterinary, and ophthalmic products. The company also commercializes food supplements and over-the-counter products, produces and sells items primarily within the generics market, and handles the import, marketing, distribution, and sales of pharmaceutical products across various therapeutic areas, including cardiovascular conditions, vaccines, antibiotics, gastro-intestinal ailments, and hormone-related treatments, among others. Its pharmaceutical operations are further bolstered by platforms situated in Ireland, Chile, Spain, and Mexico. Founded in 1991, OPKO Health, Inc. maintains its corporate headquarters in Miami, Florida.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Weak
48/100

Analyst Ratings

β“˜
Consensus
Buy
10 analysts
Strong Buy2
Buy5
Hold3
Sell0
Strong Sell0
Ratings as of Oct 2026

Latest News & Updates

GlobeNewsWireΒ·2d ago

OPKO Health to Report Third Quarter 2026 Financial Results on November 4, 2026

MIAMI, Oct. 28, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc.Β (OPKO) (NASDAQ: OPK), a multinational biopharmaceutical company, today announced that it will report operating and financial results for the third quarter 2026 o

GlobeNewsWireΒ·3d ago

OPKO Health's OPKO Biologics Doses First Participant in Phase 1/2a Trial of OPK-8801001 for Acromegaly

KIRYAT GAT, Israel, Oct. 27, 2026 (GLOBE NEWSWIRE) -- OPKO Biologics Ltd., an OPKO Health company (NASDAQ: OPK), today announced that the first participant has been dosed in a first-in-human Phase 1/2a clinical trial of

Zacks Investment ResearchΒ·13d ago

OPKO Health to Sell Select BioReference Assets to Labcorp for $722M

OPK's $722M BioReference asset sale to Labcorp, with a potential $150M earnout, aims to sharpen its biopharma focus and expand access to the 4Kscore Test.

BenzingaΒ·14d ago

OPKO Health Sheds Diagnostics Businesses in Major Labcorp Deal

Labcorp Holdings Inc. (NYSE:LH) stock traded higher Thursday after the company agreed to acquire select assets of BioReference Health from OPKO Health Inc. (NASDAQ:OPK) in a deal worth up to $872 million.

PRNewsWireΒ·15d ago

Labcorp Enters into Agreement with OPKO Health to Acquire Select Assets of BioReference Health

Acquisition will expand access to clinical laboratory services, including a broad specialty testing menu for patients and providers nationwide BURLINGTON, N.C. and MIAMI, Fla.

Defense WorldΒ·23d ago

Comparing Ardent Health (NYSE:ARDT) & OPKO Health (NASDAQ:OPK)

Ardent Health (NYSE: ARDT - Get Free Report) and OPKO Health (NASDAQ: OPK - Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength